Updated:
FHI Foundation
Founded in 1990 and anchored in Durham, North Carolina, FHI Foundation exists as the financial engine supporting FHI 360. Chair Albert Siemens, the former CEO...
FHI Foundation
Founded in 1990 and anchored in Durham, North Carolina, FHI Foundation exists as the financial engine supporting FHI 360. Chair Albert Siemens, the former CEO of FHI 360, and Investment Committee Chair Edward Whitehorne oversee the vehicle. The corpus grew from fees earned conducting clinical trials for pharmaceutical companies, notably Merck & Co. and Quintiles, rather than from a single industrialist's fortune. The endowment's deployment strategy spans venture, buyout, distressed debt, secondaries, and fund-of-funds commitments, with a generalist posture that includes a dedicated venture portfolio. FHI Ventures acts as the foundation's direct investment arm for emerging companies. A representative transaction is the 2013 sale of a clinical services unit, Novella Clinical, to Quintiles, which likely returned capital to the endowment's balance sheet. The portfolio is managed solely from the foundation's headquarters in Durham. Investment governance rests with a board-level committee chaired by Edward Whitehorne, who also chairs FHI Clinical, a related for-profit clinical research organization. The foundation benefits from a professional network that includes the Milken Institute and the PEPFAR Scientific Advisory Board. The trust maintains a physical real estate asset in the FHI 360 headquarters building at 359 Blackwell Street. No external offices or separate private trust companies are listed. Its structural differentiation lies in the endowment's tight coupling with an operational parent. Unlike typical philanthropic foundations, FHI Foundation's corpus was built by the very organization it funds, creating a self-reinforcing cycle where investment returns and the operating entity's cash flows are historically intertwined. The governance model mixes scientific, development, and finance expertise, with trustees simultaneously holding seats on the FHI 360 board.
General information
Firm type
Endowment / Foundation
Year founded
1990
Location
Region
North America
Country
United States
City
Durham
Corporate office
359 Blackwell Street, Suite 200, Durham, NC 27701, United States
Principals
Albert J. Siemens
Chair
Edward W. Whitehorne
Trustee and Chair of the Investment Committee
Rhonda M. Smith
Treasurer and Trustee
Aron Betru
Trustee
Scott Wu
Trustee
Sector focus
Frequently asked questions
How does the FHI Foundation's investment portfolio support FHI 360?
The foundation's investment returns provide unrestricted funding for FHI 360's operational budget and strategic initiatives, focusing heavily on HIV/AIDS research and related global development work. The arrangement evolved from FHI 360's own clinical trial revenues, which originally built the endowment.
Who actually makes the investment decisions at the FHI Foundation?
Edward W. Whitehorne chairs the foundation's Investment Committee, which reports to the board of trustees. The board includes individuals with ties to FHI 360's legacy, like Albert Siemens, and outside expertise, such as Aron Betru of the Milken Institute.
Does the foundation invest directly in companies, or only through funds?
It does both. The core portfolio uses a fund-of-funds approach across venture, growth, and buyout strategies. Separately, FHI Ventures functions as the direct investment vehicle for the foundation, targeting early-stage companies that align with the parent organization's global mission.
What is the relationship between the FHI Foundation and FHI Clinical?
FHI Clinical is a for-profit clinical research organization that was spun out of FHI 360's operations. The foundation's Investment Committee Chair, Edward Whitehorne, serves as Chairman of FHI Clinical, creating a direct governance link between the endowment's financial managers and the commercial entity.
Where did the FHI Foundation's capital originally come from?
The endowment was seeded from fees and royalties generated by FHI 360's clinical research work, particularly trials conducted for pharmaceutical partners such as Merck & Co. and Quintiles. Quintiles later acquired a clinical services unit from the foundation in 2013.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: